These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 8587165

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S, Hiraoka M, Inoue M, Tomatsu K, Hirano M, Mitsuhashi S.
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [Abstract] [Full Text] [Related]

  • 23. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y, Hirose T, Tanaka N, Hikichi Y, Shigeta S, Shiraiwa Y, Kameoka H, Yoshida H, Tazaki H, Iri H.
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
    Ishii Y, Ueda C, Kouyama Y, Tateda K, Yamaguchi K.
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T, Otsuki M, Hatano K, Nishihara Y.
    Chemotherapy; 1994 Apr; 40(3):167-82. PubMed ID: 8205935
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H, Ito C, Yoshida T, Watanabe K, Mori T, Ohno I, Okada S, Igari J, Arakawa M, Igarashi K, Oguri T, Okada M, Ozaki K, Terai T, Aoki N, Inoue H, Nakadate T, Kitamura N, Sekine O, Suzuki Y, Ando M, Suga M, Sato K, Nakata K, Kusano N.
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1991)].
    Ikemoto H, Watanabe K, Mori T, Igari J, Oguri T, Kondou T, Kobayashi K, Satou K, Matsumiya H, Saito A.
    Jpn J Antibiot; 1995 Aug; 48(8):965-98. PubMed ID: 7474326
    [Abstract] [Full Text] [Related]

  • 34. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000--I. Gram-positive bacteria].
    Suzuki Y, Nishinari C, Endo H, Tamura C, Jinbo K, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2002 Apr; 55(2):139-53. PubMed ID: 12071093
    [Abstract] [Full Text] [Related]

  • 35. [beta-lactamase-producing activity and antimicrobial susceptibility of major pathogenic bacteria isolated from clinical samples. Japan beta-lactamase Research Group].
    Oguri T, Igari J, Hiramatsu K, Watanabe A, Inoue M, Abe M, Yamane N, Aihara M, Hashimoto H, Japan Beta-Lactamase Research Group.
    Jpn J Antibiot; 2002 Sep; 55 Suppl A():1-28. PubMed ID: 12599526
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS, Lee WS, Bai KJ, Lam C, Hsu CW, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Chen RJ, Hsueh PR.
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
    Mendes C, Hsiung A, Kiffer C, Oplustil C, Sinto S, Mimica I, Zoccoli C, Mystic Study Group.
    Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
    [Abstract] [Full Text] [Related]

  • 40. [Antimicrobial activities of clavulanic acid/amoxicillin against freshly isolated clinical strains from outpatients].
    Koguchi M, Suzuki Y, Tanaka S, Fukayama S, Ishihara R, Deguchi K, Oda S, Nakane Y, Fukumoto T.
    Jpn J Antibiot; 1995 Dec; 48(12):1920-34. PubMed ID: 8587166
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.